Trials / Completed
CompletedNCT03275103
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 355 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cevostamab | Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles. |
| DRUG | Tocilizumab | Tocilizumab will be administered as premedication during Cycle 1. |
Timeline
- Start date
- 2017-09-19
- Primary completion
- 2026-01-07
- Completion
- 2026-01-07
- First posted
- 2017-09-07
- Last updated
- 2026-02-05
Locations
17 sites across 4 countries: United States, Australia, Canada, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03275103. Inclusion in this directory is not an endorsement.